Effects And Mechanisms Of Troglitazone On GH3 Cell In Culture

Pituitary adenomas acount for approximately 15% of intracranial tumors. Some pituitary tumors secret hormone such as prolactin and growth hormone, and in most of these PRL- and GH-secreting pituitary adenomas, dopamine agonists and /or somatostatin analogues effectively suppress PRL and GH hypersecretion, respectively and control tumor growth or induce tumor shrinkage. Nevertheless ,a subset of patients with PRL- and GH-secreting pituitary adenomas do not respond to or are intolerant of these drugs. Non-functioning pituitary adenomas are general macroadenomas and cause significant morbidity and ultimately mortality. No effective drug therapies for nonfunctioning pituitary adenomas currently exist. Therefore, with the thorough development of research on molecular pathogenesis of pituitary adenomas. It's essential to search suitable target of drug action and exploit novel, safe and effective drug for pituitary adenomas, which can enhance the curative effect of pituitary adenomas, especially nonfunctioning pituitary adenomas, macro-pituitary adenomas and invasive pituitary adenomas.ObjectiveTo study the antitumor effects of thiazolidinedione compounds—troglitazone, which is a strong affinity ligand of peroxisome proliferrator- activated receptor–γ, on rat pituitary adenomas GH3 cell line in culture and explore the mechanisms for this antitumor effects preliminarily.Methods...